59412-12-3

Basic information

• Product Name: DICHLOROQUINOLINE(2,5-)
• Synonyms: DICHLOROQUINOLINE(2,5-);2,5-DICHLOROQUINOLINE;Quinoline, 2,5-dichloro-
• CAS NO: 59412-12-3
• Molecular Formula: C₉H₅Cl₂N
• Molecular Weight: 198.05
• Mol File: 59412-12-3.mol

Chemical Properties

• Melting Point: 76-77 °C(Solv: hexane (110-54-3))
• Boiling Point: 304.0±22.0 °C(Predicted)
• Appearance: /
• Density: 1.407±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.77±0.50(Predicted)
• CAS DataBase Reference: DICHLOROQUINOLINE(2,5-)(CAS DataBase Reference)
• NIST Chemistry Reference: DICHLOROQUINOLINE(2,5-)(59412-12-3)
• EPA Substance Registry System: DICHLOROQUINOLINE(2,5-)(59412-12-3)

Safety Data

• Hazardous Substances Data: 59412-12-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
DICHLOROQUINOLINE(2,5-) is used as an intermediate in the synthesis of various pharmaceuticals for its ability to be incorporated into the molecular structures of different drugs, enhancing their therapeutic effects.
Used in Agrochemical Industry:
DICHLOROQUINOLINE(2,5-) is used as an intermediate in the production of agrochemicals, where it can be utilized to develop compounds that protect crops from pests and diseases.
Used in Antimalarial Applications:
DICHLOROQUINOLINE(2,5-) is studied as a potential anti-malarial drug due to its capacity to inhibit the growth of the malaria parasite, offering a new avenue for treating this widespread disease.
Used in Antimicrobial Applications:
DICHLOROQUINOLINE(2,5-) is used as an antimicrobial agent for its ability to combat various types of bacteria, which can be beneficial in both medical and agricultural settings to prevent infections and protect crops.
Used in Antifungal Applications:
DICHLOROQUINOLINE(2,5-) is used as an antifungal agent, leveraging its properties to inhibit the growth of fungi, which can be applied in medicine to treat fungal infections and in agriculture to protect plants from fungal diseases.

Upstream product

• 90224-97-8 5-chloroquinoline 1-oxide 
• 23981-22-8 5-chloro-2-quinolone 
• 635-27-8 5-chloroquinoline 
• 611-34-7 5-Aminoquinoline 
• 445041-60-1 (E)-N-(3-chlorophenyl)-3-ethoxypropenamide 

Downstream Products

• 1404491-66-2 5-chloro-2-(3,5-dimethylphenyl)quinoline 
• 1064137-50-3 2,5-dichloroquinoline-3-carbaldehyde 
• 1065479-84-6 N-((S)-1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine 
• 1065480-13-8 N-((R)-1-(5-chloro-2-(3-fluoro-phenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine 
• 1065480-15-0 N-(1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine 
• 1065482-48-5 2-(1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)isoindoline-1,3-dione 
• 1065482-47-4 1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethanol 
• 1065482-49-6 1-(5-chloro-2-(3-fluorophenyl)quinolin-3-yl)ethanamine 
• 1065482-46-3 5-chloro-2-(3-fluorophenyl)quinoline-3-carbaldehyde 
• 59412-13-4 2,5-dichloro-3-phenyl-quinoline 
• 1423778-37-3 5-chloro-2-(phenylethynyl)quinoline 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds of formula I' and formula II' and their pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity for the treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity.

2-(Substituted ethynyl)quinoline Derivatives as mGLUr5 Antagonists

Provided is a 2-(substituted ethynyl)quinoline derivative having an mGluR5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mGluR5 receptor

Synthesis and biological evaluation of 2-(arylethynyl)quinoline derivatives as mGluR5 antagonists for the treatment of neuropathic pain

We described here the synthesis and biological evaluation of mGluR5 antagonists containing a quinoline ring structure. Using intracellular calcium mobilization assay (FDSS assay), we identified compound 5n, showing high inhibitory activity against mGluR5. In addition, it was found that compound 5n has excellent stability profile. Finally, this compound exhibited favorable analgesic effects in spinal nerve ligation model of neuropathic pain, which is comparable to gabapentin.

Molecular recognition via triplex formation of mixed purine/pyrimidine DNA sequences using oligoTRIPs

Stable DNA triple-helical structures are normally restricted to homopurine sequences. We have described a system of four heterocyclic bases (TRIPsides) that, when incorporated into oligomers (oligoTRIPs), can recognize and bind in the major groove to any

Synthesis of a fluorine-18-labelled derivative of 6-nitroquipazine, as a radioligand for the in vivo serotonin transporter imaging with PET.

Considerable efforts have been engaged in the design, synthesis and pharmacological characterization of radioligands for imaging the serotonin transporter, based on its implication in several neuropsychiatric diseases, such as depression, anxiety and schizophrenia. In the 5-halo-6-nitroquipazine series, the fluoro derivative has been designed for positron emission tomography (PET). The corresponding 5-iodo-, 5-bromo- and 5-chloro N-Boc-protected quipazines as labelling precursors, as well as 5-fluoro-6-nitroquipazine as a reference compound have been synthesized. 5-[(18)F]Fluoro-6-nitroquipazine has been radiolabelled with fluorine-18 (positron-emitting isotope, 109.8 min half-life) by nucleophilic aromatic substitution from the corresponding N-Boc protected 5-bromo- and 5-chloro-precursors using K[(18)F]F-K(222) complex in DMSO by conventional heating (145 degrees C, 2 min) or microwave activation (50 W, 30-45 s), followed by removal of the protective group with TFA. Typically, 15-25 mCi (5.5-9.2 GBq) of 5-[(18)F]fluoro-6-nitroquipazine (1-2 Ci/micromol or 37-72 GBq/micromol) could be obtained in 70-80 min starting from a 550-650 mCi (20.3-24.0 GBq) aliquot of a cyclotron [(18)F]F(-) production batch (2.7-3.8% non decay-corrected yield based on the starting [(18)F]fluoride). Ex vivo studies (biodistribution in rat), as well as PET imaging (in monkey) demonstrated that 5-[(18)F]fluoro-6-nitroquipazine ([(18)F]-1d) readily crossed the blood brain barrier and accumulated in the regions rich in 5-HT transporter (frontal- and posterial cortex, striata). However, the low accumulation of the tracer in the thalamus (rat and monkey) as well as the comparable displacement of the tracer observed with both citalopram, a -HT re-uptake inhibitor and maprotiline, a norepinephrine re-uptake inhibitor (rat), indicate that 5-[(18)F]fluoro-6-nitroquipazine ([(18)F]-1d) does not have the suggested potential for PET imaging of the serotin transporter (SERT).

II. Synthesis and biological evaluation of some bioisosteres and congeners of the antitumor agent, 2-{4-[(7-chloro-2-quinoxalinyl)oxylphenoxy}propionic acid (XK469)

XK469 (1) is among the most highly and broadly active antitumor agents to have been evaluated in our laboratories. Subsequent developmental studies led to the entry of (R)-(+) 1 (NSC 698215) into phase 1 clinical trials (NIH UO1-CA62487). The antitumor me